Overview

Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

Gynecologic Oncology Group

Treatments:

Epothilone B
Epothilones